Education
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
MIRM Analyst Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MIRM Stock 12 Month Forecast
Average Price Target
$96.67
▲(47.09% Upside)
| Highest Price Target$130.00 | Average Price Target$96.67 | Lowest Price Target$81.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Leerink Partners
$90→$100
Buy
52.16%
Upside
Reiterated
12/10/25
H.C. Wainwright
$81
Buy
23.25%
Upside
Reiterated
12/09/25
Evercore ISI
$89→$94
Buy
43.03%
Upside
Reiterated
12/09/25
Strategic Acquisition and Market Potential Drive Buy Rating for Mirum PharmaceuticalsWe model $800M peak for now Inc MIRM | $68.48 Outperform | $94.00 (from $89.00) Target - 1971 1 FactSet This report is prepared solely for the use of Landscape: brelovitug has 300mg QW dosing (which can fit into a 900mg QM dosing arm (HCP-admin). GILD’s bulevirtide is approved in the EU + working on US approval at 10mg. It is QD subQ dosing and less efficacious, so we don’t view them as competitor.
Morgan Stanley
$81→$95
Buy
44.55%
Upside
Reiterated
12/09/25
Robert W. Baird
$80→$88
Buy
33.90%
Upside
Reiterated
12/09/25
Cantor Fitzgerald
$95→$130
Buy
97.81%
Upside
Reiterated
12/08/25
TD Cowen
$95
Buy
44.55%
Upside
Reiterated
11/12/25
Citizens JMP
$81→$95
Buy
44.55%
Upside
Reiterated
11/05/25
Stifel Nicolaus
$89→$92
Buy
39.99%
Upside
Reiterated
11/05/25
J.P. Morgan
$53→$77
Buy
17.16%
Upside
Reiterated
09/12/25
Citi
$89
Buy
35.42%
Upside
Reiterated
08/18/25
Analysts Are Bullish on These Healthcare Stocks: Mirum Pharmaceuticals (MIRM), Century Therapeutics (IPSC)We hosted Mirum co-founder and CEO a virtual fireside chat (replay HERE). We discussed the company’s rare disease franchise specializing in developing ileal bile acid transporter (IBATs) to target cholestatic disorders, which are caused by bile acid buildup due to reduced/blocked flow from the liver. IBATs can significantly decrease the debilitating itching (aka pruritus) symptoms experienced by patients. Mirum’s primary asset in Livmarli is approved for two cholestatic genetic diseases and has been outperforming sales expectations over the past few quarters, bringing in $88.2M most recently in 2Q25. Mgt believes a potential label expansion for Livmarli to patients with other ultra-rare choleastic diseases could propel the drug to blockbuster status.
Raymond James
$77→$82
Buy
24.77%
Upside
Reiterated
08/07/25
Westpark Capital
$66→$72
Buy
9.56%
Upside
Reiterated
02/27/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Leerink Partners
$90→$100
Buy
52.16%
Upside
Reiterated
12/10/25
H.C. Wainwright
$81
Buy
23.25%
Upside
Reiterated
12/09/25
Evercore ISI
$89→$94
Buy
43.03%
Upside
Reiterated
12/09/25
Strategic Acquisition and Market Potential Drive Buy Rating for Mirum PharmaceuticalsWe model $800M peak for now Inc MIRM | $68.48 Outperform | $94.00 (from $89.00) Target - 1971 1 FactSet This report is prepared solely for the use of Landscape: brelovitug has 300mg QW dosing (which can fit into a 900mg QM dosing arm (HCP-admin). GILD’s bulevirtide is approved in the EU + working on US approval at 10mg. It is QD subQ dosing and less efficacious, so we don’t view them as competitor.
Morgan Stanley
$81→$95
Buy
44.55%
Upside
Reiterated
12/09/25
Robert W. Baird
$80→$88
Buy
33.90%
Upside
Reiterated
12/09/25
Cantor Fitzgerald
$95→$130
Buy
97.81%
Upside
Reiterated
12/08/25
TD Cowen
$95
Buy
44.55%
Upside
Reiterated
11/12/25
Citizens JMP
$81→$95
Buy
44.55%
Upside
Reiterated
11/05/25
Stifel Nicolaus
$89→$92
Buy
39.99%
Upside
Reiterated
11/05/25
J.P. Morgan
$53→$77
Buy
17.16%
Upside
Reiterated
09/12/25
Citi
$89
Buy
35.42%
Upside
Reiterated
08/18/25
Analysts Are Bullish on These Healthcare Stocks: Mirum Pharmaceuticals (MIRM), Century Therapeutics (IPSC)We hosted Mirum co-founder and CEO a virtual fireside chat (replay HERE). We discussed the company’s rare disease franchise specializing in developing ileal bile acid transporter (IBATs) to target cholestatic disorders, which are caused by bile acid buildup due to reduced/blocked flow from the liver. IBATs can significantly decrease the debilitating itching (aka pruritus) symptoms experienced by patients. Mirum’s primary asset in Livmarli is approved for two cholestatic genetic diseases and has been outperforming sales expectations over the past few quarters, bringing in $88.2M most recently in 2Q25. Mgt believes a potential label expansion for Livmarli to patients with other ultra-rare choleastic diseases could propel the drug to blockbuster status.
Raymond James
$77→$82
Buy
24.77%
Upside
Reiterated
08/07/25
Westpark Capital
$66→$72
Buy
9.56%
Upside
Reiterated
02/27/25
Best Analysts Covering Mirum Pharmaceuticals
1 Month
xxx
Success Rate
19/32 ratings generated profit
Average Return
+2.62%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 59.38% of your transactions generating a profit, with an average return of +2.62% per trade.
3 Months
xxx
Success Rate
21/32 ratings generated profit
Average Return
+10.59%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 65.63% of your transactions generating a profit, with an average return of +10.59% per trade.
1 Year
2 Years
xxx
Success Rate
32/32 ratings generated profit
Average Return
+96.83%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +96.83% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MIRM Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
0
0
0
0
2
Buy
13
17
18
15
15
Hold
6
5
6
4
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
22
24
19
22
Each month's total comprises the sum of three months' worth of ratings.
MIRM Financial Forecast
MIRM Stock Forecast FAQ
What is MIRM’s average 12-month price target, according to analysts?
Based on analyst ratings, Mirum Pharmaceuticals Inc’s 12-month average price target is 96.67.
What is MIRM’s upside potential, based on the analysts’ average price target?
Mirum Pharmaceuticals Inc has 47.09% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MIRM a Buy, Sell or Hold?
Mirum Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
What is Mirum Pharmaceuticals Inc’s price target?
The average price target for Mirum Pharmaceuticals Inc is 96.67. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $130.00 ,the lowest forecast is $81.00. The average price target represents 47.09% Increase from the current price of $65.72.
The highest analyst price target is $130.00 ,the lowest forecast is $81.00. The average price target represents 47.09% Increase from the current price of $65.72.
What do analysts say about Mirum Pharmaceuticals Inc?
Mirum Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of MIRM?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.